Rebates are unrelated to US drugmakers' pricing strategies, says PCMA

As the US Trump Administration considers modifying price concessions for prescription drugs in Medicare and federal programs, the Pharmaceutical Care Management Association (PCMA)is releasing new data, "Reconsidering Drug Prices, Rebates, and PBMs," showing drug manufacturers alone set prices – independent of rebates.

Pharmacy benefit managers (PBMs) have long encouraged manufacturers to offer payers alternative ways to reduce net costs. Simply put, the easiest way to lower costs would be for drug companies to lower their prices.

Click here to see the new research.